A Philadelphia judge granted summary judgment in the case of a woman who said her breast cancer was caused by her ingestion of hormone-replacement therapy drugs because the plaintiff did not have any evidence to show that the one prescriber she identified had done more than refill her prescription.
In a second HRT decision, another Philadelphia judge said that two defense verdicts in dual HRT cases tried together in 2010 should be upheld because Wyeth, now owned by Pfizer, presented several experts to show that the women’s breast cancer could have been caused by factors other than HRT.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
